N6-methyladenosine of TRIM27 enhances the stem cell-type phenotype of cisplatin-resistant colorectal cancer cells

Jun-Qiong Zheng; Ying Zhan; Wen-Jing Huang; Zhi-Yong Chen; Wei-Hao Wu

doi:10.1016/j.bbrep.2023.101572

N6-methyladenosine of TRIM27 enhances the stem cell-type phenotype of cisplatin-resistant colorectal cancer cells

Biochem Biophys Rep. 2023 Nov 9:36:101572. doi: 10.1016/j.bbrep.2023.101572. eCollection 2023 Dec.

Authors

Jun-Qiong Zheng¹, Ying Zhan¹, Wen-Jing Huang¹, Zhi-Yong Chen¹, Wei-Hao Wu¹

Affiliation

¹ Department of Medical Oncology, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, Fujian, China.

Abstract

Colorectal cancer (CRC), classified as a lethal form of cancer, substantially threatens human well-being. Cancer stem cells (CSCs) reflect subsets for cancerous cells having basic stem-cell type properties, being significantly involved in the development of chemoresistance and tumor relapsing. The aberrant TRIM27 expression in various types of cancer indicates its potential involvement in cancer growth and progression. The current understanding of the TRIM27 involvement in CRC remains limited. In current study indicated that TRIM27 can potentially promote CSC-type phenotype of Cisplatin (DDP)-resistant CRC cells. YTHDF1 recruitment onto m⁶A-amended TRIM27 was crucial for facilitating the TRIM27 translating process in DDP-resistant CRC cells. The present research proposes that TRIM27 exhibits an oncogenic role by enhancing the CSC-type properties in DDP-resistant CRC via the m⁶A-modified pathway. The potential therapy for combating the relapse of CRC may include TRIM27 and YTHDF1, as they have been found to have significant roles in promoting CSC-type phenotypic characteristics.

Keywords: Cancer stem cell; Colorectal cancer; TRIM27; YTHDF1; m6A.